A Phase 2 interventional study of Lebrikizumab and Placebo in Atopic Dermatitis, sponsored by Hoffmann-La Roche. Completed at 74 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-10-02.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing lebrikizumab in Dermatitis, Atopic — 4 open to participants now, 7 under way, 4 of them phase 3. lebrikizumab · Dermatitis, Atopic.
Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, this one is the 17th largest by enrollment, is one of 2 that started in 2015, is one of 3 in phase 2, and was the 1st registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 24 studies testing lebrikizumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Australia and 10 more countries
Ages 6 mo–18 yrs
Forefront Dermatology S.C · Sites in United States
Ages 12+
Almirall, S.A.
Ages 12+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 212 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 252 across the 24 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 24 have an industry lead sponsor. The 6 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 6 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
3 of the studies testing lebrikizumab in Dermatitis, Atopic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06526182Phase 3Almirall, S.A.A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis | 2027-04-25 |
| NCT06906497Johann E Gudjonsson MD PhDLebrikizumab in Moderate-to-severe Atopic Dermatitis | 2027-07 |
| NCT07856134Forefront Dermatology S.CAD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of lebrikizumab administered subcutaneously (SC) in adult participants with persistent moderate to severe atopic dermatitis (AD) who are inadequately controlled by topical corticosteroids (TCS). The study includes a screening visit, a 2-week run-in period, a 12-week blinded treatment period, and an 8-week safety follow-up period. Following screening visit, eligible participants will enter in run-in period (Days - 14 to - 1) during which a protocol-specified topical therapy regimen will be initiated. At the end of the run-in period, participants who have: 1) demonstrated compliance with the protocol-specified TCS regimen, and 2) who continue to fulfill the eligibility criteria will be randomized.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive lebrikizumab 250 milligrams (mg) SC single dose on Day 1 followed by placebo on Week 4 and Week 8. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
Drug: Lebrikizumab · Drug: Placebo · Drug: TCS Cream
Participants will receive lebrikizumab 125 mg SC single dose on Day 1 followed by placebo on Week 4 and Week 8. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
Drug: Lebrikizumab · Drug: Placebo · Drug: TCS Cream
Participants will receive lebrikizumab 125 mg SC every 4 weeks (Q4W) for a total of 3 doses. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
Drug: Lebrikizumab · Drug: TCS Cream
Participants will receive placebo Q4W for a total of 3 doses. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
Drug: Placebo · Drug: TCS Cream
Lebrikizumab will be administered SC as per the schedule specified in the respective arms.
Placebo matching to lebrikizumab will be administered as per the schedule specified in the respective arms.
TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily
Percentage of Participants Achieving a 50 Percent (%) Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-50) at Week 12
Time frame: Week 12
Percent Change From Baseline in EASI Score at Week 12
Time frame: Baseline, Week 12
Absolute Change From Baseline in EASI Score at Week 12
Time frame: Baseline, Week 12
Percentage of Participants Achieving a 75% Reduction From Baseline in EASI Score (EASI-75) at Week 12
Time frame: Week 12
Percentage of Participants Achieving an Investigator's Global Assessment (IGA) score of 0 or 1 at Week 12
Time frame: Week 12
Percentage of Participants With a Greater Than or Equal to (>/=) 2 Point Reduction From Baseline in IGA at Week 12
Time frame: Week 12
Absolute Change From Baseline in IGA at Week 12
Time frame: Baseline, Week 12
Percentage of Participants Achieving an Investigator Global Signs Assessment (IGSA) Score of 0 or 1 at Week 12
Time frame: Week 12
Percentage of Participants with a >/=2 Point Reduction From Baseline in IGSA at Week 12
Time frame: Week 12
Absolute Change From Baseline in IGSA at Week 12
Time frame: Baseline, Week 12
Percent Change From baseline in Severity Scoring of Atopic Dermatitis (SCORAD) at Week 12
Time frame: Baseline, Week 12
Absolute Change From baseline in SCORAD at Week 12
Time frame: Baseline, Week 12
Percentage of Participants With a 50% or 75% Reduction From Baseline in SCORAD-50/75 at Week 12
Time frame: Week 12
Percentage of Participants Achieving EASI-50 at Week 12 and Maintaining EASI-50 at Weeks 16
Time frame: Weeks 12, 16
Percentage of Participants Achieving EASI-50 at Week 12 and Maintaining EASI-50 at Weeks 16 and 20
Time frame: Weeks 12, 16, 20
Percentage of Participants Achieving IGA Score of 0 or 1 at Week 12 and Maintaining IGA Score of 0 or 1 at Weeks 16
Time frame: Weeks 12, 16
Percentage of Participants Achieving IGA Score of 0 or 1 at Week 12 and Maintaining IGA Score of 0 or 1 at Weeks 16 and 20
Time frame: Weeks 12, 16, 20
Percentage of Participants Achieving IGSA Score of 0 or 1 at Week 12 and Maintaining IGSA Score of 0 or 1 at Weeks 16
Time frame: Weeks 12, 16
Percentage of Participants Achieving IGSA Score of 0 or 1 at Week 12 and Maintaining IGSA Score of 0 or 1 at Weeks 16 and 20
Time frame: Weeks 12, 16, 20
Percentage of Participants Achieving SCORAD-50 at Week 12 and Maintaining SCORAD-50 at Weeks 16
Time frame: Weeks 12, 16
Percentage of Participants Achieving SCORAD-50 at Week 12 and Maintaining SCORAD-50 at Weeks 16 and 20
Time frame: Weeks 12, 16, 20
Percent Change From Baseline in Total % Body Surface Area (BSA) Affected At Week 12
Time frame: Baseline, Week 12
Absolute Change From Baseline in Pruritus as Measured by the Pruritus Visual Analog Scale (VAS) at Week 12
Time frame: Baseline, Week 12
Percent Change From Baseline in Pruritus as Measured by the Pruritus VAS at Week 12
Time frame: Baseline, Week 12
Absolute Change From Baseline in Pruritus as Measured by the 5-D Itch Scale at Week 12
Time frame: Baseline, Week 12
Percent Change From Baseline in Pruritus as Measured by the 5-D Itch Scale at Week 12
Time frame: Baseline, Week 12
Total Use (Grams) of TCS From Baseline to Week 12
Time frame: From Baseline to Week 12
Total Use (Grams) of TCS From Week 12 to End of Study or Early Termination
Time frame: From Week 12 to end of study or early termination (up to approximately 20 weeks)
Number of Disease Flares From Baseline to Week 12
Time frame: From Baseline to Week 12
Change in AD Symptoms From Baseline to Week 12, as Assessed by the Atopic Dermatitis Symptom Diary (ADSD)
Time frame: Baseline, Week 12
Change in AD-Specific HealthRelated Quality of Life (QoL) From Baseline to Week 12, as Assessed by the Atopic Dermatitis Impact Questionnaire (ADIQ)
Time frame: Baseline, Week 12
Change in Health-Related QoL From Baseline to Week 12, as Measured by the Dermatology Life Quality Index (DLQI)
Time frame: Baseline, Week 12
Percentage of Participants With Treatment-Emergent Adverse Events (AEs)
Time frame: From start of run-in period (Day -14) until study completion (up to approximately 20 Weeks)
Percentage of Participants With Anti-Therapeutic Antibodies (ATA) to Lebrikizumab
Time frame: Pre-dose on Days 1, 29, 85, 141, study discontinuation visit (up to Day 141)
Percentage of Participants With ATA to Phospholipase B-Like 2 (PLBL2) Protein
Time frame: Pre-dose on Days 1, 29, 85, 141, study discontinuation visit (up to Day 141)
Percentage of Participants With Disease Rebound
Time frame: From Week 12 up to approximately 20 weeks
Maximum Serum Concentration (Cmax) of Lebrikizumab
Time frame: After first dose of lebrikizumab at Week 1
Time to Reach Cmax (Tmax) of Lebrikizumab
Time frame: After first dose of lebrikizumab at Week 1
Minimum Serum Concentration (Cmin) of Lebrikizumab
Time frame: Pre-dose at Weeks 4, 8, 12
Elimination Half-Life (t1/2) of Lebrikizumab
Time frame: Pre-dose on Days 1, 8, 29, 43, 57, 85, 113, 141, study discontinuation visit (up to Day 141)
The record gives a start of May 2015, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lebrikizumab